Search the Newsreel

Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks

Sanofi ADR earnings beat by $1.30, revenue topped estimates

Sanofi Q2 Net Profit Plunges, Business Profit Climbs On Strong Sales; Lifts FY26 Outlook

(RTTNews) - French drug major Sanofi SA (SNY, SNYNF, SAN.PA) reported Thursday sharply lower net profit in its second quarter, while business earnings climbed from last year with strong sales growth. Further, the firm upgraded its fiscal 2026 outlook. For fiscal 2026, the pharmaceutical …

Sanofi drug pipeline worries, Dupixent dependence shake shares

Sanofi's shares dropped 8% despite raising its full-year sales forecast due to strong Dupixent demand, as investors were concerned about pipeline cuts and the company's reliance on the blockbuster drug. The drugmaker scrapped the development of two treatments and announced a strategic review of …

Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded

Sanofi Winthrop Industrie Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded July 30, 2026 Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09 Pharma launches sales increased by 48.3%, reaching €1.3 billion, driven …

Sanofi halts amlitelimab trials, preps Q2 2026 earnings amid AI drug discovery push

Sanofi is preparing to report its Q2 2026 earnings, with expected EPS of $1.10 and revenue of $12.41 billion. The company has ceased clinical development of amlitelimab for atopic dermatitis, indicating a shift in its drug pipeline. Sanofi is also intensifying its focus on …

Sanofi Korea, postpartum care group renew MOU to strengthen infection prevention

Sanofi Korea and the Korea Postpartum Association have renewed their Memorandum of Understanding (MOU) to enhance cooperation in infection prevention and management for mothers and newborns. This extension builds upon their initial 2023 agreement, under which they've conducted educational programs and awareness campaigns, including …

The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.)

Key Points Sanofi is growing well, thanks in large part to its drug Dupixent. It has more drugs in development, some of which could turn into big sellers. Its stock is appealingly priced, too.10 stocks we like better than Sanofi › If you've got …

Sanofi and Servier execs talk oncology: Pitches, Europe's position, and China's advantage

Executives from Sanofi and Servier discussed the evolving oncology licensing landscape, highlighting divergent approaches to assessing potential partnerships and the increasing competitive threat from China. They emphasized the need for European biotech companies to increase their speed and competitiveness, while also leveraging their strengths …

Sanofi (SNY) discloses $534M portfolio across 10 positions in latest 13F

Sanofi (SNY) has filed its latest 13F Holdings Report, revealing a U.S. equity portfolio valued at $534,041,662 across 10 distinct positions. The report confirms Sanofi as the sole institutional investment manager for these holdings, with the filing signed by Alexandra Roger, Head of Legal …

Sanofi Announces Executive Leadership Reshuffle

Sanofi has announced a significant reshuffle of its Executive Committee, integrating senior figures from across its commercial, research, and global divisions to support its next phase of growth starting September 1, 2026. Belén Garijo, CEO, emphasized that the updated leadership team will focus on …

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Sanofi announced it will not submit amlitelimab for global regulatory reviews in moderate-to-severe atopic dermatitis, discontinuing its clinical development for this indication. The decision follows a strategic assessment where the drug, despite some positive results in a long-term extension study, was deemed not to …

Sanofi halts development of troubled immune drug in eczema

Sanofi has halted the development of amlitelimab, an experimental eczema drug it once considered a potential successor to Dupixent, due to mixed late-stage study results and safety concerns. This decision follows similar setbacks for other OX40L-targeting antibodies and raises questions about Sanofi's research pipeline, …

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

Sanofi has decided to abandon its plans to seek approval for amlitelimab, an eczema drug acquired through its $1.1 billion Kymab buyout, for atopic dermatitis. The company stated that the drug would not offer a "meaningful improvement" over existing treatments, despite previous phase 3 …

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

Sanofi has announced it will not seek regulatory approval for its eczema drug, amlitelimab, after data review indicated it doesn't support further development. This decision comes as the French pharmaceutical company undergoes a pipeline review under its new chief executive. While the eczema application …

Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped

Sanofi has scrapped most of its ongoing trials for amlitelimab, an autoimmune asset acquired from Kymab, in atopic dermatitis following its failure to significantly improve over the standard of care in Phase 3 studies. This decision, part of a strategic pipeline assessment, comes despite …

Sanofi abandons eczema drug approval efforts in another blow to OX40 class

Sanofi has decided to discontinue the development of its immunology therapy, amlitelimab, for atopic dermatitis (AD), citing a lack of meaningful differentiation from existing treatments. This decision is a setback for Sanofi, which had hoped amlitelimab would succeed its blockbuster drug Dupixent, and further …

Fatal gene-editing trial in China raises ethics and oversight questions

A six-year-old girl has died in China after receiving an experimental, brain-directed CRISPR therapy, sparking significant ethical and oversight concerns. This tragic event was reported in conjunction with other biotech news, including an FDA panel narrowly voting to allow compounding pharmacies to produce certain …

Sanofi Discontinues Development of OX40L Inhibitor Amlitelimab in Atopic Dermatitis

Sanofi has discontinued the clinical development of amlitelimab for moderate to severe atopic dermatitis (AD), citing insufficient efficacy and safety data to significantly improve upon current standard-of-care treatments. Despite long-term data from the ESTUARY study showing durable maintenance of clinical response, Sanofi concluded that …

Sanofi ends amLitelimab program in atopic dermatitis amid portfolio review

Sanofi has discontinued the development of its anti‑OX40L monoclonal antibody, amLitelimab, for moderate to severe atopic dermatitis, concluding that its efficacy and safety data do not warrant regulatory submissions or significant improvement over existing treatments. This decision is part of a broader strategic portfolio …

Scribe Therapeutics Sets IPO Of 8.58 Mln Shares At $15/Shr; Enters Private Placement With Sanofi

(RTTNews) - Scribe Therapeutics Inc. (SCTX), a clinical-stage biotechnology company, announced pricing of its upsized initial public offering of 8.58 million shares of its common stock at the high end of the range at a public offering price of $15 per share. In addition …

Popular insulin product enters shortage as other pens leave market

Sanofi's Lantus Solostar pen, a popular long-acting insulin product, is experiencing supply issues due to increased demand and broader market dynamics, prompting users to struggle with finding the medication. While not officially designated an FDA shortage, the company anticipates the situation will improve in …

Sanofi’s New CEO Has A Simple To-Do List: Deals Or Buybacks

Berenberg, an investment bank, suggests Sanofi's CEO Belén Garijo needs to either pursue acquisitions to drive growth and close a "deep" valuation gap or implement a EUR5 billion share buyback program that could boost earnings per share by about 5%. The bank emphasizes the …

Sanofi (SNY) to Post Quarterly Earnings on Thursday

Sanofi Elevates Top US Atty To General Counsel

French pharmaceutical company Sanofi SA announced the promotion of its North American general counsel to group general counsel. This change follows the departure of the current legal chief after four years in the role. The article, however, does not provide the name of the …

FDA issues untitled letters to Sanofi and Viatris for false advertising

The FDA's Office of Prescription Drug Promotion has sent untitled letters to Sanofi and Viatris for making misleading claims in their product promotions. Sanofi was cited for an email promoting Beyfortus, which incorrectly suggested it prevents general RSV, while Viatris was reprimanded for a …

How AI is Reshaping the Patient Care Journey

Sanofi is leveraging Digital and AI technologies to transform the patient care journey, addressing fragmentation from diagnosis to long-term treatment. Their approach spans pre-prescription (identification and diagnosis) and post-prescription (onboarding and support) phases. By integrating AI-driven tools like AccelRare, FabryFind, iCare+, and Companion App, …

FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV

The FDA has issued an untitled letter to Sanofi regarding its promotional emails for the RSV antibody Beyfortus. The agency claims Sanofi's emails create a "misleading impression" by presenting Beyfortus as a general RSV preventative, rather than specifically for lower respiratory tract disease as …

Amundi group (SNY) reports 68.7M-share, 5.65% beneficial ownership position in Sanofi

Amundi and its subsidiary Amundi Asset Management have disclosed a beneficial ownership of 68,651,904 Sanofi common shares, representing 5.65% of the class. They report shared voting power over 36,655,093 shares and shared dispositive power over all 68,651,904 shares. A significant portion of these shares …

Cincinnati startup Enable Injections scores significant FDA win

Cincinnati-based startup Enable Injections, in collaboration with Sanofi, received FDA approval for its CirCliq device. This approval marks a significant milestone for the company, which continues to expand its hiring in the region. The firm is recognized as a local unicorn within the biotech …

Sanofi continues tweaks to executive roster as new CEO Garijo settles in

Sanofi is continuing to adjust its executive team under new CEO Belén Garijo, with several notable changes including expanding the role of vaccine chief Thomas Triomphe to include China, and Madeleine Roach becoming president for Germany, Switzerland, and Austria. The company also announced the …

Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter

Sanofi has announced significant changes to its Executive Committee, effective September 1, 2026, to streamline leadership across its businesses, R&D, and global functions. These changes are intended to support the company's strategic priorities and prepare for its next growth chapter. Key appointments include new …

Lobbying Update: $920,000 of SANOFI US SERVICES INC lobbying was just disclosed

SANOFI US SERVICES INC (SNY) disclosed $920,000 in lobbying expenditures for Q2 2026, covering a wide range of issues including drug pricing, FDA regulations, and vaccine-related matters. Concurrently, an analysis of hedge fund activity shows significant changes in SNY stock holdings, with some institutions …

SANOFI : Gets a Neutral rating from JP Morgan

JP Morgan has reaffirmed its "Neutral" rating for Sanofi, maintaining an unchanged target price of EUR 95. This news comes amidst a broader context of European equities trading lower in the US and various other announcements related to Sanofi's drug approvals and research collaborations.

Sanofi survey uncovers Type 1 diabetes misconceptions and screening gaps

A new survey commissioned by Sanofi reveals widespread misconceptions about Type 1 diabetes and significant gaps in screening. Many adults are unaware that Type 1 diabetes can manifest in adulthood and are hesitant to get screened despite identifying as at risk. The findings suggest …

Devika Gupta Joins Sanofi as Head of Value for Healthcare Systems & Economics

Sanofi has appointed Devika Gupta as Head of Value for Healthcare Systems & Economics to bolster its market access, pricing, and value-based healthcare strategies globally. Gupta brings over 25 years of experience from previous leadership roles at Merck, Pfizer, Campbell Alliance, Johnson & Johnson …